Global Hunter Securities Initiates Coverage on Corcept Therapeutics. (CORT) with a Buy
Tweet Send to a FriendGet Alerts CORT Hot Sheet
Price: $1.85 +2.21%
Rating Summary:
5 Buy, 3 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
5 Buy, 3 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade CORT Now!
Global Hunter Securities initiates coverage on Corcept Therapeutics. (Nasdaq: CORT) with a Buy rating. PT $5.
Global analyst says, "CORLUX – a potentially effective treatment option with a clean mechanism of action. We believe Corlux has therapeutic value in lowering cortisol levels in Cushing’s patients. Its MOA is well understood as an antagonist of the GR-II receptor, one of two receptors to which cortisol binds to initiate the cascade of events needed in response to stressful stimuli. Compared to other therapeutic agents like ketoconazole, CORLUX may be better tolerated, which may yield greater efficacy."
To see all the upgrades/downgrades on shares of CORT, visit our Analyst Ratings page.
Corcept Therapeutics Incorporated (Corcept) is a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Global analyst says, "CORLUX – a potentially effective treatment option with a clean mechanism of action. We believe Corlux has therapeutic value in lowering cortisol levels in Cushing’s patients. Its MOA is well understood as an antagonist of the GR-II receptor, one of two receptors to which cortisol binds to initiate the cascade of events needed in response to stressful stimuli. Compared to other therapeutic agents like ketoconazole, CORLUX may be better tolerated, which may yield greater efficacy."
To see all the upgrades/downgrades on shares of CORT, visit our Analyst Ratings page.
Corcept Therapeutics Incorporated (Corcept) is a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Deutsche Bank Starts Kodiak Oil & Gas (KOG) at Hold
- Topeka Capital Starts Atmel (ATML) at Buy
- Deutsche Bank Resumes CenterPoint Energy (CNP) at Hold
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
